Anuh Pharma Reports Financial Results for March 2026; Total Revenue Reaches 77,601.30 Lakh

Anuh Pharma Reports Financial Results for March 2026; Total Revenue Reaches 77,601.30 Lakh​

Anuh Pharma Limited released its audited financial results for the quarter and year ended March 31, 2026. The company reported total revenue of 77,601.30 Lakh for the year, a slight dip compared to the previous year's figure of 66,151.49 Lakh. The Profit After Tax stood at 4,104.61 Lakh for the financial year ended March 31, 2026.

According to the financial statements, the company’s Total Comprehensive Income for the period ended March 31, 2026, was 1,138.80 Lakh.

Quarterly Financial Performance Summary​

The company’s financial performance is detailed below, comparing the results for the three months ended March 31, 2026, against the same period in 2025.

The financial results are presented in Lakhs of Rupees.

Key Financial Indicators Show Mixed Trends​

Analyzing the other financial indicators reveals varying trends in the company's operational efficiency.

Balance Sheet Position as of March 31, 2026​

As of March 31, 2026, Anuh Pharma reported total assets of 55,736.79 Lakh. The company recorded total equity of 35,222.24 Lakh and total liabilities of 20,514.55 Lakh.

The total assets are comprised of Non-current Assets (10,605.23 Lakh) and Current Assets (45,131.56 Lakh). Major components of current assets include Inventories (14,775.50 Lakh) and Trade receivables (23,863.28 Lakh).

Total equity and liabilities stood at 35,222.24 Lakh for equity, with 214.22 Lakh recorded under non-current liabilities. Current liabilities were substantial, totaling 55,736.79 Lakh.

Cash Flow Summary​

The Statement of Cash Flows for the year ended March 31, 2026, detailed the company’s cash generation and utilization:

• Cash Generated from Operations: The company generated 1,023.14 Lakh from operating activities, after accounting for direct taxes paid of 1,324.30 Lakh.
• Cash Used in Investing Activities: Investing activities saw a net usage of 1,784.15 Lakh, driven primarily by investments and capital expenditures.
• Cash Used in Financing Activities: Total cash used in financing activities was 12,632.75 Lakh, reflecting dividend payments and payments related to borrowings.

The net change in cash and cash equivalents for the period was a usage of 1,149.76 Lakh, bringing the cash and cash equivalents at the end of the period to 805.97 Lakh.

Corporate and Operational Highlights​

Several key operational and corporate actions were noted in the financial period:

• Bonus Shares: During the quarter ended September 30, 2025, the shareholders approved the issuance of 1:1 bonus shares, resulting in the allotment of 5,01,12,000 bonus equity shares on July 16, 2025.
• Dividend Recommendation: The Board of Directors recommended a final dividend of Rs. 1.50 per equity share of face value of Rs. 5 each (30%), subject to shareholder approval.
• Labor Codes Impact: The company assessed the financial implications of the consolidation of multiple existing labour legislations into the 'New Labour Codes' effective November 21, 2025. This change resulted in an increase in gratuity liability and leave liability by Rs. 48.31 Lakhs.

ANUHPHR Stock Price Movement​

On Wednesday, Anuh Pharma Limited shares edged higher to close at ₹81.19, gaining 2.18% on the day. The stock settled above its previous close, supported by a sizable trading volume of 71,721 shares.